LONDON–(BUSINESS WIRE)–According to a delegate voting poll taken at the latest series of Fitch Solutions ‘Managing Credit & Counterparty Risk’ seminars this month, 43% of risk managers remain unsure if the new Basel III regulations will help them manage risk more effectively, whilst 32% believe it will improve effectiveness and, in contrast, 25% believe it will not.

“These results indicate the continued uncertainty in the market on the impact of these regulations, particularly with regards to the treatment of the Credit Value Adjustment under Basel III,” said Thomas Aubrey, Managing Director, Fitch Solutions, London.

When asked whether regulatory uncertainty, the European sovereign debt crisis or rising inflation was the most key issue facing the risk management industry, 52% voted for the European sovereign debt crisis, closely followed by 43% selecting regulatory uncertainty, whilst rising inflation was considered much less of a concern with only 5% of votes.

“Our managing credit and counterparty risk seminars serve as a valuable forum for delegates to share their knowledge, experiences and to discuss potential solutions to these regulatory challenges,” Aubrey added.

The ‘Managing Credit & Counterparty Risk’ seminars took place in Paris, Milan and Frankfurt on 6, 7 and 13 April respectively and, overall, attracted over 200 market practitioners working mainly in risk, credit, credit and counterparty risk and portfolio management functions. For further information on the event series, see ‘Fitch Solutions Hosts Managing Credit & Counterparty Risk Seminars,’ published 21 March 2011 and available at

Further information about Fitch Solutions can be found at

Fitch Solutions, a division of the Fitch Group, focuses on the development of fixed-income products and services, bringing to market a wide range of data, analytical tools and related services. The division is also the distribution channel for Fitch Ratings content.

The Fitch Group also includes Fitch Ratings and Algorithmics, and is a majority-owned subsidiary of Fimalac, S.A. For additional information, please visit ‘‘; ‘‘; ‘‘; and ‘‘.